Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.

Autor:	Wu TC; Department of Radiation Oncology, University of California, Los Angeles., Luterstein E; University of California San Diego School of Medicine, San Diego., Neilsen BK; Department of Radiation Oncology, University of California, Los Angeles., Goldman JW; Department of Medicine, University of California, Los Angeles., Garon EB; Department of Medicine, University of California, Los Angeles., Lee JM; Division of Thoracic Surgery, Department of Surgery, University of California, Los Angeles., Felix C; Department of Radiation Oncology, University of California, Los Angeles., Cao M; Department of Radiation Oncology, University of California, Los Angeles., Tenn SE; Department of Radiation Oncology, University of California, Los Angeles., Low DA; Department of Radiation Oncology, University of California, Los Angeles., Kupelian PA; Varian Medical Systems, Palo Alto, California., Steinberg ML; Department of Radiation Oncology, University of California, Los Angeles., Lee P; Department of Radiation Oncology, University of California, Los Angeles.; Now with Department of Radiation Oncology, City of Hope Orange County, Lennar Foundation Cancer Center, Irvine, California.
Jazyk:	angličtina
Zdroj:	JAMA oncology [JAMA Oncol] 2024 Mar 01; Vol. 10 (3), pp. 352-359.
DOI:	10.1001/jamaoncol.2023.6033
Abstrakt:	Importance: Intrathoracic progression remains the predominant pattern of failure in patients treated with concurrent chemoradiation followed by a consolidation immune checkpoint inhibitor for locally advanced, unresectable non-small cell lung cancer (NSCLC). Objective: To determine the maximum tolerated dose (MTD) and use of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative radiotherapy (SABR) boost. Design, Setting, and Participants: This was an early-phase, single-institution, radiation dose-escalation nonrandomized controlled trial with concurrent chemotherapy among patients with clinical stage II (inoperable/patient refusal of surgery) or III NSCLC (American Joint Committee on Cancer Staging Manual, seventh edition). Patients were enrolled and treated from May 2011 to May 2018, with a median patient follow-up of 18.2 months. Patients advanced to a higher SABR boost dose if dose-limiting toxic effects (any grade 3 or higher pulmonary, gastrointestinal, or cardiac toxic effects, or any nonhematologic grade 4 or higher toxic effects) occurred in fewer than 33% of the boost cohort within 90 days of follow-up. The current analyses were conducted from January to September 2023. Intervention: All patients first received 4 Gy × 10 fractions followed by an adaptive SABR boost to residual metabolically active disease, consisting of an additional 25 Gy (low, 5 Gy × 5 fractions), 30 Gy (intermediate, 6 Gy × 5 fractions), or 35 Gy (high, 7 Gy × 5 fractions) with concurrent weekly carboplatin/paclitaxel. Main Outcome and Measure: The primary outcome was to determine the MTD. Results: Data from 28 patients (median [range] age, 70 [51-88] years; 16 [57%] male; 24 [86%] with stage III disease) enrolled across the low- (n = 10), intermediate- (n = 9), and high- (n = 9) dose cohorts were evaluated. The protocol-specified MTD was not exceeded. The incidences of nonhematologic acute and late (>90 days) grade 3 or higher toxic effects were 11% and 7%, respectively. No grade 3 toxic effects were observed in the intermediate-dose boost cohort. Two deaths occurred in the high-dose cohort. Two-year local control was 74.1%, 85.7%, and 100.0% for the low-, intermediate-, and high-dose cohorts, respectively. Two-year overall survival was 30.0%, 76.2%, and 55.6% for the low-, intermediate-, and high-dose cohorts, respectively. Conclusions and Relevance: This early-phase, dose-escalation nonrandomized controlled trial showed that concurrent chemoradiation with an adaptive SABR boost to 70 Gy in 15 fractions with concurrent chemotherapy is a safe and effective regimen for patients with locally advanced, unresectable NSCLC. Trial Registration: ClinicalTrials.gov Identifier: NCT01345851.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu